NextCure files IND for product candidate LNCB74

NextCure, Inc.

Filed Investigational New Drug application with FDA for LNCB74.
Updated corporate presentation to reflect the IND filing.
Company engaging with investment community starting December 5, 2024.

item 7.01 item 9.01

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-016026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.